Semiannual Report to Congress

October 1, 2008 – March 31, 2009
Office of the Inspector General

Drug Enforcement Administration
DEA logo The DEA enforces federal laws and regulations related to the growth, production, or distribution of controlled substances. In addition, the DEA seeks to reduce the supply of and demand for illicit drugs, both domestically and internationally. The DEA has approximately 10,800 employees staffing its 21 division offices in the United States and the Caribbean and 87 offices in 63 other countries.


During this reporting period, the OIG received 202 complaints involving the DEA. The most common allegations made against DEA employees were job performance failure, off-duty misconduct, waste, and mismanagement. The OIG opened eight investigations and referred other allegations to the DEA’s Office of Professional Responsibility for review.

At the close of the reporting period, the OIG had 20 open cases of alleged misconduct against DEA employees. The most common allegation was improper release of information. The following are examples of cases involving the DEA that the OIG’s Investigations Division handled during this reporting period:

Ongoing Work

Follow-up on the DEA’s Handling of Cash Seizures

This follow-up review is assessing if the DEA has taken appropriate actions to implement our prior audit recommendations for handling cash seizures and whether the DEA’s corrective actions have improved its handling of seized cash.

The DEA’s Clandestine Drug Laboratory Cleanup Program

The OIG is evaluating the effectiveness of the DEA’s Clandestine Laboratory Cleanup Program.

The DEA’s El Paso Intelligence Center

The OIG is reviewing how the DEA’s El Paso Intelligence Center provides intelligence support to federal, state, and local law enforcement agencies.


« Previous Table of Contents Next »